Accessibility Menu
Prestige Consumer Healthcare Stock Quote

Prestige Consumer Healthcare (NYSE: PBH)

$63.38
(1.4%)
+0.89
Price as of October 22, 2025, 12:21 p.m. ET

KEY DATA POINTS

Current Price
$63.38
Daily Change
(1.4%) +$0.89
Day's Range
$62.28 - $63.45
Previous Close
$62.49
Open
$62.54
Beta
0.48
Volume
127,867
Average Volume
524,541
Market Cap
3.1B
Market Cap / Employee
$62.49M
52wk Range
$60.15 - $90.04
Revenue
-
Gross Margin
0.54%
Dividend Yield
N/A
EPS
$4.26
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Prestige Consumer Healthcare Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PBH-12.36%+81.13%+12.62%+252%
S&P+15.06%+95.03%+14.29%+463%

Prestige Consumer Healthcare Company Info

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$249.53M-6.6%
Gross Profit$135.15M-3.7%
Gross Margin54.16%1.6%
Market Cap$3.95B15.4%
Market Cap / Employee$6.58M0.0%
Employees6005.3%
Net Income$47.47M-3.3%
EBITDA$79.42M-0.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$139.50M307.2%
Accounts Receivable$168.41M-1.9%
Inventory153.10.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.03B-5.9%
Short Term Debt$8.60M93.3%

Ratios

Q2 2025YOY Change
Return On Assets6.32%0.2%
Return On Invested Capital4.90%0.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$78.18M45.8%
Operating Free Cash Flow$79.01M44.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings17.5618.3020.0618.7311.21%
Price to Book2.132.232.382.153.96%
Price to Sales3.253.493.783.5514.26%
Price to Tangible Book Value-3.07-3.47-4.06-4.0039.21%
Price to Free Cash Flow TTM14.1615.7017.6914.865.77%
Enterprise Value to EBITDA50.0149.3848.5561.478.81%
Free Cash Flow Yield7.1%6.4%5.7%6.7%-5.45%
Return on Equity12.6%12.6%12.3%12.0%-7.18%
Total Debt$1.06B$1.03B$1.04B$1.04B-5.45%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.